CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 169 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q1 2022. The put-call ratio across all filers is 0.65 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $66,784,325 | -18.6% | 2,426,756 | +0.4% | 0.50% | +19.6% |
| Q2 2023 | $82,000,531 | +0.5% | 2,416,756 | +6.6% | 0.41% | -21.9% |
| Q1 2023 | $81,602,244 | +18.1% | 2,267,989 | +46.3% | 0.53% | -3.8% |
| Q4 2022 | $69,083,500 | +69.6% | 1,550,000 | +7.0% | 0.55% | +111.9% |
| Q3 2022 | $40,730,000 | +133.4% | 1,448,934 | +123.8% | 0.26% | +152.4% |
| Q2 2022 | $17,454,000 | -59.0% | 647,420 | -48.2% | 0.10% | -46.4% |
| Q1 2022 | $42,575,000 | +10.2% | 1,250,000 | +25.0% | 0.19% | +32.4% |
| Q4 2021 | $38,640,000 | -1.0% | 1,000,000 | +38.3% | 0.14% | -8.8% |
| Q3 2021 | $39,026,000 | +133.4% | 722,843 | +44.6% | 0.16% | +117.8% |
| Q2 2021 | $16,720,000 | +62.3% | 500,000 | 0.0% | 0.07% | +14.1% |
| Q1 2021 | $10,300,000 | -41.2% | 500,000 | -50.0% | 0.06% | -39.6% |
| Q4 2020 | $17,520,000 | – | 1,000,000 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 2,600,000 | $88,218,000 | 12.13% |
| Octagon Capital Advisors LP | 759,898 | $25,783,339 | 3.59% |
| TSP Capital Management Group, LLC | 251,895 | $8,546,800 | 3.08% |
| ACUTA CAPITAL PARTNERS, LLC | 122,343 | $4,151,098 | 2.81% |
| 5AM Venture Management, LLC | 310,270 | $10,527,461 | 2.62% |
| COMMODORE CAPITAL LP | 631,665 | $21,432,393 | 2.41% |
| RTW INVESTMENTS, LP | 3,463,201 | $117,506,410 | 2.24% |
| Eversept Partners, LP | 785,740 | $26,660,158 | 2.23% |
| Redmile Group, LLC | 1,696,004 | $57,545,416 | 2.21% |
| Affinity Asset Advisors, LLC | 87,031 | $2,952,962 | 1.03% |